CRL Earnings Date: Nov 4, 2026 (Estimated) — Charles River Laboratories International, Inc.
NYSE · Healthcare · Diagnostics & Research
Updated
When is CRL's next earnings date?
Charles River Laboratories International, Inc. (CRL) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $2.97 on revenue of $960.4M.
How did CRL do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Charles River Laboratories International, Inc. posted EPS of $3.02 versus the $2.74 estimate, a beat of 10.6%. Revenue was $1.00B against a $977.2M estimate. The stock's 1-day post-earnings move was +11.4%.
How much does CRL stock move after earnings?
CRL beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.2% (up or down) in the day after earnings.
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | 2.74 | 3.02 | +10.62% | $1.00B | ✅ Beat | +11.36% | +20.45% | +24.62% |
| 2026-05-07 | Q1 2026 | 1.95 | 2.06 | +5.64% | $995.8M | ✅ Beat | -0.03% | -10.39% | -0.21% |
| 2026-02-18 | Q4 2025 | 2.34 | 2.39 | +2.14% | $994.2M | ✅ Beat | -0.33% | +4.75% | -0.90% |
| 2025-11-05 | Q3 2025 | 2.33 | 2.43 | +4.29% | $1.00B | ✅ Beat | -5.71% | -2.45% | +3.48% |
| 2025-08-06 | Q2 2025 | 2.50 | 3.12 | +24.80% | $1.03B | ✅ Beat | -10.25% | -8.80% | -3.09% |
| 2025-02-19 | Q4 2024 | 2.53 | 2.66 | +5.14% | $1.00B | ✅ Beat | +6.87% | +8.23% | +12.62% |
| 2024-08-07 | Q2 2024 | 2.39 | 2.80 | +17.15% | $1.03B | ✅ Beat | -12.60% | -11.06% | -16.44% |
| 2024-05-09 | Q1 2024 | 2.07 | 2.27 | +9.66% | $1.01B | ✅ Beat | -2.21% | -1.16% | -8.71% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $1.00B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Discovery and Safety Assessment | 60.4% | $606.5M | -1.9% | $603.3M | $592.6M | $618.0M | $600.7M |
| Research Models and Services | 20.9% | $209.5M | -1.8% | $204.3M | $213.1M | $213.3M | $213.5M |
| Manufacturing Support | 18.7% | $188.1M | -6.3% | $194.9M | $178.5M | $200.8M | $190.7M |
By region
Q2 FY26 · $991.0M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 54.5% | $539.9M | -1.8% | $547.0M | $537.0M | $549.9M | $537.6M |
| Europe | 26.5% | $263.1M | -6.7% | $263.3M | $263.3M | $281.9M | $277.7M |
| CANADA | 12.9% | $127.5M | -6.0% | $119.4M | $125.4M | $135.6M | $116.8M |
| Asia Pacific | 6.1% | $60.5M | +11.0% | $55.8M | $41.9M | $54.5M | $51.7M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.